Cubist Systematic Strategies LLC boosted its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 143.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 19,942 shares of the biopharmaceutical company’s stock after buying an additional 11,766 shares during the period. Cubist Systematic Strategies LLC’s holdings in Sangamo Therapeutics were worth $299,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of SGMO. RA Capital Management LLC purchased a new position in Sangamo Therapeutics in the second quarter valued at approximately $11,000,000. State Street Corp raised its holdings in Sangamo Therapeutics by 51.6% in the second quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock valued at $16,441,000 after buying an additional 636,296 shares during the period. Vanguard Group Inc. raised its holdings in Sangamo Therapeutics by 12.4% in the second quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock valued at $30,551,000 after buying an additional 384,031 shares during the period. Balyasny Asset Management LLC purchased a new position in Sangamo Therapeutics in the second quarter valued at approximately $3,095,000. Finally, American Century Companies Inc. purchased a new position in Sangamo Therapeutics in the third quarter valued at approximately $5,145,000. Hedge funds and other institutional investors own 64.33% of the company’s stock.
In other news, VP Curt A. Herberts III sold 16,630 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $16.13, for a total transaction of $268,241.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Saira Ramasastry sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $14.67, for a total transaction of $73,350.00. Following the sale, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $73,350. The disclosure for this sale can be found here. Insiders sold 53,433 shares of company stock valued at $894,146 in the last ninety days. 5.50% of the stock is owned by corporate insiders.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The company had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. During the same quarter last year, the company earned ($0.27) earnings per share. Sangamo Therapeutics’s revenue for the quarter was up 333.0% on a year-over-year basis. equities research analysts forecast that Sangamo Therapeutics, Inc. will post -0.73 EPS for the current fiscal year.
Several brokerages have issued reports on SGMO. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Piper Jaffray Companies set a $25.00 price objective on shares of Sangamo Therapeutics and gave the company a “buy” rating in a research report on Wednesday. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Barclays began coverage on shares of Sangamo Therapeutics in a research report on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price objective for the company. Finally, Wedbush reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Sangamo Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $18.83.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics, Inc. (NASDAQ:SGMO).
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.